Table 1 Clinical characteristics of 160 systemic sclerosis patients
|  | N = 160 (%) |
|---|---|
Female | 138 (86.3) |
Diffuse cutaneous SSc | 88 [55] |
Modified Rodnan skin score (median (IQR) | 6.5 (4;12) |
Modified Rodnan skin score (median (IQR) in diffuse cutaneous SSc | 10 (6;15) |
Modified Rodnan skin score (median (IQR) in limited cutaneous SSc | 4 (2;7) |
Presence of Raynaud’s phenomenon | 154 (96.3) |
Current digital ulcers | 12 (7.5) |
Digital ulcer ever (including current) | 52 (32.5) |
Presence of current synovitis | 18 (11.3) |
Joint contractures | 91 (56.9) |
New York Heart Association cardiac state III–IV | 13 (8.1) |
Exertional dyspnoea | 100 (62.5) |
Lung fibrosis detected by high-resolution computer tomography | 97 (60.6) |
Cardiac involvement | 93 (58.1) |
Pulmonary arterial hypertension by right heart catheterization | 5 (3.1)a |
Scleroderma renal crisis | 1 (0.6) |
Mild gastrointestinal involvement by UCLA GIT 2.0 | 123 (76.9) |
Moderate gastrointestinal involvement by UCLA GIT 2.0 | 22 (13.8) |
Severe gastrointestinal involvement by UCLA GIT 2.0 | 15 (9,4) |
Malabsorption | 21 (13.1) |
Gastrointestinal pseudo-obstruction | 3 (1.9) |
Use of cyclic antibiotics for gastrointestinal dysmotility | 18 (11.3) |
Gastric vascular ectasia | 3 (1.9) |
Anti-centromere | 35 (21.9) |
Anti-topoisomerase I | 39 (24.4) |
Anti-RNA polymerase III | 22 (13.8) |
Anti-PmScl | 16 (10) |
Anti-Ku | 6 (3.8) |
Anti-Th/To | 7 (4.4) |
Anti-Nor90 | 4 (2.5) |
Anti-U3RP | 3 (1.9) |
No scleroderma-specific antibody | 55 (34.4) |
Rheumatoid factor | 53 (33.1) |
Anti-cylic citrullinated peptide | 10 (6.3) |